This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

10 Nov 2021

Meiji Seika to expand CDMO business with new manufacturing facility in India

The $20.1 million investment will enable the company to manufacture pharma products for the Adcock Ingram Group and for other clients

Japan's Meiji Seika Pharma has announced plans to construct a new manufacturing facility in Bengaluru, India to expand its CMO capacity.

Construction will take place at an existing plant run by Adcock Ingram, which manufactures and distributes pharmaceutical products for the South African, European and Oceanian markets.

The company anticipates the new $20.1 miilion manufacturing facility with a total floor space of 7878 m2 to be up and running in March 2023.

The site will have the annual capacity to produce 750 million tablets, 75 million sachets and 4 milion bottles not only for the Adcock Ingram Group, but also for other clients.

The move forms part of the Meiji Group's 2023 pharmaceutical plan to expand its CMO/CDMO business. In a statement, the company said: "We will continue to optimise our production bases in Japan and overseas to strengthen our production system and establish a system for the stable supply of highly reliable pharmaceuticals."

Related News